Junshi's lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market

Junshi Biosciences has delivered the data to challenge Amgen and Sanofi for a cardiovascular disease opportunity, with the results of two phase 3 anti-PCSK9 antibody trials advancing the Chinese biotech toward approval in its home market.